Recursion Pharmaceuticals Management
Management criteria checks 1/4
Recursion Pharmaceuticals' CEO is Najat Khan, appointed in Jan 2026, has a tenure of 1.75 years. total yearly compensation is $9.19M, comprised of 3.1% salary and 96.9% bonuses, including company stock and options. directly owns 0.003% of the company’s shares, worth $64.24K. The average tenure of the management team and the board of directors is 1.2 years and 10.3 years respectively.
Key information
Najat Khan
Chief executive officer
US$9.2m
Total compensation
| CEO salary percentage | 3.10% |
| CEO tenure | no data |
| CEO ownership | 0.003% |
| Management average tenure | 1.2yrs |
| Board average tenure | 10.3yrs |
Recent management updates
Recent updates
Recursion Pharmaceuticals: Stock Unresponsive To Clinical Updates
Jan 16Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Reported Third-Quarter Earnings And Analysts Are Lifting Their Estimates
Nov 07
Recursion: FDA To Replace Animal Testing With AI? - A Small But Necessary Win
Apr 11Recursion: A Look At Near-Term Phase 1b And Phase 2 Catalysts
Mar 27
REC-617 And REC-994 Trials Will Drive Future AI-Driven Drug Discovery Success
Successful clinical trials and expanded pipeline indicate promising future revenue growth and earnings from potential drug market entries.Recursion Pharmaceuticals: Stretched Thin And Chasing Unicorns
Mar 12This Just In: Analysts Are Boosting Their Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Outlook for This Year
Mar 02Recursion Pharmaceuticals Needs A Clinical Breakthrough To Pique Interest
Feb 14Recursion: Investors Will Need To Be Patient
Jan 10Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected
Dec 25Recursion: Undruggable CDK12 Protein Target Might Be Possible With REC-1245
Dec 09Recursion: No News Isn't Good News When It Comes To Vanilla Pipeline
Nov 20Analysts Are Betting On Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) With A Big Upgrade This Week
Nov 10Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) Share Price Could Signal Some Risk
Nov 08Recursion: AI Is Only As Good As The Data
Sep 11Recursion: Path Forward For REC-994 Remains Despite Mixed Response
Sep 04Earnings Beat: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
Aug 12Recursion Pharmaceuticals: AI-Driven 'TechBio' With Upcoming Catalysts
Aug 01Recursion Pharmaceuticals: More Of A TechBio Industrializing Drug Discovery
Jun 24Recursion Pharmaceuticals: Catalysts Are Coming And Success Is A Must
Jun 14Revenues Not Telling The Story For Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) After Shares Rise 25%
May 22Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
May 12CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | -US$716m |
| Jun 30 2025 | n/a | n/a | -US$649m |
| Mar 31 2025 | n/a | n/a | -US$575m |
| Dec 31 2024 | US$9m | US$285k | -US$464m |
Compensation vs Market: Najat's total compensation ($USD9.19M) is above average for companies of similar size in the US market ($USD6.85M).
Compensation vs Earnings: Insufficient data to compare Najat's compensation with company performance.
CEO
Najat Khan (40 yo)
Dr. Najat Khan, Ph D is Chief Executive Officer and President of Recursion Pharmaceuticals, Inc. January 1, 2026. She was Chief R&D Officer and Chief Commercial Officer of Recursion Pharmaceuticals, Inc. f...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 12.2yrs | US$8.50m | 1.08% $ 26.2m | |
| CEO, President & Director | no data | US$9.19m | 0.0027% $ 64.2k | |
| CFO & President of Recursion UK | 1.2yrs | US$8.59m | 0.037% $ 883.4k | |
| Chief Medical Officer | 2.6yrs | US$1.93m | 0.014% $ 345.8k | |
| Chief Operating Officer | 1.2yrs | no data | no data | |
| Chief Technology Officer | 6yrs | no data | no data | |
| Chief Scientific Officer | 1.2yrs | no data | 0.0055% $ 132.1k | |
| Chief Legal Officer & Corporate Secretary | 2.3yrs | no data | no data | |
| Chief Communications Officer | no data | no data | no data | |
| Chief People and Impact Officer | 1.2yrs | no data | no data | |
| Chief Business Officer | 1.2yrs | no data | no data | |
| Chief Platform Officer | no data | no data | no data |
Experienced Management: RXRX's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 12.2yrs | US$8.50m | 1.08% $ 26.2m | |
| CEO, President & Director | 1.8yrs | US$9.19m | 0.0027% $ 64.2k | |
| Member of Business Advisory Panel | 11.2yrs | no data | no data | |
| Member of Business Advisory Panel | 11.6yrs | no data | no data | |
| Chairman of Therapeutics Advisory Board | 4.5yrs | no data | no data | |
| Vice-Chairman & Lead Independent Director | 5.8yrs | US$316.48k | 0.0099% $ 240.0k | |
| Independent Director | 7.4yrs | no data | 0.0018% $ 43.5k | |
| Independent Director | 13yrs | US$294.98k | 1.27% $ 30.8m | |
| Member of Scientific and Technical Advisory Board | 11.8yrs | no data | no data | |
| Member of Scientific & Technical Advisory Board | 11.8yrs | no data | no data | |
| Independent Director | 9.3yrs | US$304.23k | 0.023% $ 558.3k | |
| Independent Director | less than a year | no data | no data |
Experienced Board: RXRX's board of directors are seasoned and experienced ( 10.3 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/16 20:54 |
| End of Day Share Price | 2026/01/15 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Recursion Pharmaceuticals, Inc. is covered by 15 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gaurav Goparaju | Berenberg |
| Gal Munda | Berenberg |
| Alec Stranahan | BofA Global Research |